|
Mar 6
|
Zai Lab Announces Participation in March Investor Conference
|
|
Jan 10
|
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
|
|
Dec 22
|
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
|
|
Dec 19
|
Zai Lab Announces Participation in January Investor Conference
|
|
Dec 7
|
Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
|
|
Jun 28
|
Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
|
|
Apr 27
|
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
|
|
Apr 26
|
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
|